| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The parent compound, dexamethasone, targets the glucocorticoid receptor (GR). Agonist binding induces GR nuclear translocation, glucocorticoid-response-element activation, and transrepression of pro-inflammatory transcription factors such as NF-κB and AP-1. Dexamethasone-d4 has equivalent receptor pharmacology and is used analytically.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, dexamethasone-d4 is used as an internal standard for dexamethasone quantification. The parent compound’s activity is assessed by GR binding assays, GR-responsive luciferase reporter assays, and suppression of cytokine production in LPS-stimulated macrophages or PBMCs. |
| ln Vivo |
Dexamethasone is clinically used for inflammatory and allergic conditions and has been investigated in sepsis and COVID-19. Dexamethasone-d4 is used as an internal standard in pharmacokinetic studies. It is not used as a therapeutic agent, and no efficacy data exist for the labeled compound.
|
| Enzyme Assay |
For GR binding assays, recombinant GR ligand-binding domain is incubated with a fluorescent or radiolabeled glucocorticoid tracer in the presence of serial dilutions of dexamethasone. Binding is quantified by fluorescence polarization. For LC-MS/MS, dexamethasone-d4 is added to plasma before protein precipitation, and the analyte-to-internal-standard ratio is used for quantification.
|
| Cell Assay |
For cell-based GR reporter assays, cells expressing GR and a glucocorticoid-responsive luciferase reporter are treated with dexamethasone, and luciferase activity is measured after 24 h. Cytokine production in LPS-stimulated macrophages is measured by ELISA. Dexamethasone-d4 serves as an analytical standard.
|
| Animal Protocol |
For in vivo pharmacokinetic studies, dexamethasone is administered to rats or mice, and plasma samples are collected at serial time points. Dexamethasone-d4 is added as an internal standard, and concentrations are quantified by LC-MS/MS. Efficacy endpoints in inflammation models include edema, cytokine levels, and immune-cell infiltration.
|
| References |
| Molecular Formula |
C22H29FO5
|
|---|---|
| Molecular Weight |
396.485717535019
|
| Exact Mass |
396.225
|
| CAS # |
2483831-63-4
|
| Related CAS # |
Dexamethasone;50-02-2;Dexamethasone-d3-1
|
| PubChem CID |
76974609
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.9
|
| tPSA |
94.8
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
28
|
| Complexity |
805
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
F[C@@]12[C@]3(C=CC(C([2H])=C3C([2H])C[C@H]1[C@@H]1C[C@@H](C)[C@](C(C([2H])([2H])O)=O)([C@@]1(C)C[C@@H]2O)O)=O)C
|
| InChi Key |
UREBDLICKHMUKA-SOEBWSEYSA-N
|
| InChi Code |
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1/i4D,9D,11D2/t4?,12-,15+,16+,17+,19+,20+,21+,22+
|
| Chemical Name |
(8S,9R,10S,11S,13S,14S,16R,17R)-4,6-dideuterio-17-(2,2-dideuterio-2-hydroxyacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~30 mg/mL (~75.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5221 mL | 12.6107 mL | 25.2213 mL | |
| 5 mM | 0.5044 mL | 2.5221 mL | 5.0443 mL | |
| 10 mM | 0.2522 mL | 1.2611 mL | 2.5221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.